CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 200 enrolled
Drug / intervention
ADO II AS (PDA closure)device
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03055858
NCT03055858N/ACompleted

AMPLATZER Duct Occluder II Additional Sizes Clinical Study

Abbott Medical Devices·interventional·Posted Feb 16, 2017·Updated Feb 11, 2025

In Brief

A clinical study evaluating ADO II AS (PDA closure) for Patent Ductus Arteriosus. Completed, enrolled 200 participants across 9 sites.

Detailed Summary

The ADO II AS Study is a single arm, prospective, multicenter, nonrandomized clinical investigation to characterize the safety and effectiveness of the ADO II AS device in patients with a patent ductus arteriosus (PDA). Subjects will be implanted with the ADO II AS device using a transcatheter femoral vessel approach under fluoroscopic and echocardiographic guidance. To account for subject dropout, up to 50 subjects will be enrolled in this clinical investigation. Up to an additional 150 subjects may be enrolled under continued access. The clinical investigation will be conducted at up to 10 centers in the United States. Subjects participating in this clinical investigation will be followed for 3 years. The expected duration of enrollment is 18 months. The total duration of the clinical investigation is expected to be 4.5 years.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
2017201820192020202120222023202420252026
First PostedFeb 16, 2017
Enrollment StartJun 5, 2017
Primary CompletionSep 25, 2019
Study CompletionApr 5, 2022
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 9.4 years ago

Interventions

ADO II AS (PDA closure)device

Closure of PDA using Amplatzer Duct Occluder II Additional Sizes (ADO II AS).